Holen Sie sich die Stockscreener-App
2.785
0.18%
0.005
Schlusskurs vom Vortag:
$2.78
Offen:
$2.78
24-Stunden-Volumen:
109.18K
Relative Volume:
0.45
Marktkapitalisierung:
$276.90M
Einnahmen:
$4.60M
Nettoeinkommen (Verlust:
$-82.31M
KGV:
-3.3955
EPS:
-0.8202
Netto-Cashflow:
$-87.79M
1W Leistung:
-1.94%
1M Leistung:
+18.01%
6M Leistung:
-2.62%
1J Leistung:
+26.59%
1-Tages-Spanne:
$2.725
$2.805
1-Wochen-Bereich:
$2.725
$3.00
52-Wochen-Spanne:
$2.095
$4.00
Ac Immune Sa Stock (ACIU) Company Profile
Compare ACIU vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
2.785 | 276.41M | 4.60M | -82.31M | -87.79M | -0.8202 |
VRTX
Vertex Pharmaceuticals Inc
|
521.01 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
802.50 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,005.97 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.20 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.57 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-31 | Eingeleitet | BTIG Research | Buy |
| 2019-02-01 | Herabstufung | UBS | Buy → Neutral |
| 2019-01-04 | Eingeleitet | UBS | Buy |
| 2018-04-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-23 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2016-10-18 | Eingeleitet | Credit Suisse | Outperform |
| 2016-10-18 | Eingeleitet | Jefferies | Buy |
| 2016-10-18 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Ac Immune Sa Aktie (ACIU) Neueste Nachrichten
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why - Zacks Investment Research
AC Immune’s New Phase 1 NLRP3 Trial Puts Inflammation Strategy in Focus - TipRanks
AC Immune SA (NASDAQ: ACIU) Schedules October 2 Vote for Tom Graney's Board Nomination - Kalkine Media
AC Immune Calls October EGM to Add Veteran Biopharma Financier Tom Graney to Board - TipRanks
Parkinson's drug Fast Tracked as AC Immune (NASDAQ: ACIU) plans board changes - Stock Titan
AC Immune Ltd (NASDAQ: ACIU) Share Price, ACIU Stock News, ACIU Share Price & Updates - kalkine.ca
AC Immune reports positive phase 1 data for ACI‑19764 - PharmaTimes
AC Immune stock rating reiterated at Buy by H.C. Wainwright - Investing.com
Promising Penny Stocks To Consider In August 2026 - simplywall.st
Positive Ph1 results for AC Immune's NLRP3 inflammasome inhibitor - pharmaphorum
AC (ACIU) Financial Update: The Bottom-Line Figure Outpaces Its Comparison on the Day; After Earnings: The Market Price Moves 2.33% Higher on the DayConsensus Forecast Report - vinanet.vn
AC Immune Says Early Data from Anti-Inflammatory Drug Gives Wider Clinical Momentum for Pipeline - Benzinga
ACIU Reiterated by BTIG -- Price Target Maintained at $8.00 - GuruFocus
AC Immune's NLRP3 inhibitor reaches brain with safety intact in first human study - AllSci
AC Immune shares rise after encouraging early Phase 1 data for ACI-19764 - Yahoo Finance
AC Immune stock gains on early Phase 1 trial results By Investing.com - Investing.com Australia
AC Immune stock gains on early Phase 1 trial results - Investing.com
AC Immune posts trial data for inflammatory drug (ACIU:NASDAQ) - Seeking Alpha
AC Immune reports phase 1 safety data for NLRP3 inhibitor By Investing.com - Investing.com Nigeria
AC Immune posts positive first‑in‑human data for NLRP3 inhibitor ACI‑19764 - TipRanks
AC Immune reports phase 1 safety data for NLRP3 inhibitor - Investing.com India
AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 - The Manila Times
AC Immune (NASDAQ: ACIU) advances NLRP3 pill into heart-risk trial - Stock Titan
AC (ACIU) Levels: Advances 0.39% to $2.58 in the Latest Reading; Chart View: $2.45 and $2.71 Define the Nearby Reference LevelsInside Day Breakout - vinanet.vn
AC Immune takes Parkinson's vaccine into US trials as Phase II data near - AllSci
ACIU Q2 2026 Earnings: Surprise EPS Beat of 117.61% Offers Little Support as Shares Slip 1.91%Quarterly Financial Update - vinanet.vn
AC Immune2026 Funding Rounds & List of Investors - Tracxn
ACIU Looks 33.6% Undervalued on GF Value™ Despite Financial Chal - GuruFocus
AC Immune receives FDA fast track status for parkinson’s drug By Investing.com - Investing.com Nigeria
AC Immune Wins FDA Fast Track for ACI-7104 in Early Parkinson’s Disease - TipRanks
AC Immune receives FDA fast track status for parkinson’s drug - Investing.com
AC Immune (NASDAQ: ACIU) gains FDA Fast Track, IND clearance for Parkinson’s drug ACI-7104 - Stock Titan
AC Immune’s Parkinson’s Candidate Shows 100% Responder Rate - Stock Titan
AC Immune SA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - simplywall.st
Analyst Reiterates Buy on AC Immune as 2H26 Catalysts Approach; Price Target Maintained at $12 - tipranks.com
AC Immune (NasdaqGM:ACIU) Stock Price Shrugs Off Surprise Quarterly Profit - Sahm
ACIU Reiterated by BTIG -- Maintains Price Target at $8.00 - GuruFocus
AC Immune SA reports results for the quarter ended June 30Earnings Summary - TradingView
AC Immune Files First-Half 2026 Results and Corporate Update on Form 6-K - tipranks.com
AC Immune: Q2 Earnings Snapshot - Barchart.com
AC Immune First Half 2026 Financial and Corporate Update - The Manila Times
Partner milestones lift AC Immune (NASDAQ: ACIU) cash and cut loss - stocktitan.net
AC Immune’s Parkinson’s Trial Gets a $4 Million Grant - Stock Titan
AC Immune (ACIU) Posts Modest 2.2% Gain as Shares Trade Above $2.30 SupportMFI Overbought - dars.gov.et
ACIU Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesAnalyst Drop Coverage - vinanet.vn
AC Immune (ACIU) Drops 6.12% as Support at $2.12 Comes into FocusBuy Signal Reports - vinanet.vn
ACIU Q1 2026 Earnings: Narrowed Loss Beats Expectations as Pipeline AdvancesPretax Income Report - vinanet.vn
AC Immune SA (ACIU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AC Immune SA (ACIU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
AC Immune SA (ACIU) Institutional Confidence - TradingKey
AC Immune SA (ACIU) Cash Flow - TradingKey
Finanzdaten der Ac Immune Sa-Aktie (ACIU)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.71%
2.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):